Eton Pharmaceuticals Inc (ETON)

NASDAQ
5.010
-0.070(-1.38%)
After Hours
5.010
0.000(0.00%)
- Real-time Data
  • Volume:
    74,284
  • Bid/Ask:
    5.010/5.060
  • Day's Range:
    4.985 - 5.100

ETON Overview

Prev. Close
5.08
Day's Range
4.985-5.1
Revenue
14.89M
Open
5.06
52 wk Range
4.03-10.29
EPS
-0.56
Volume
74,284
Market Cap
123.25M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
428,739
P/E Ratio
-
Beta
-
1-Year Change
-38.75%
Shares Outstanding
24,600,175
Next Earnings Date
Nov 18, 2021
What is your sentiment on Eton Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Eton Pharmaceuticals Inc News

Eton Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellSellSell
Technical IndicatorsStrong SellStrong SellBuyStrong SellStrong Sell
SummaryStrong SellStrong SellNeutralStrong SellStrong Sell

Eton Pharmaceuticals Inc Company Profile

Eton Pharmaceuticals Inc Company Profile

Employees
16

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Read More
  • https://www.globenewswire.com/news-release/2020/09/29/2101010/0/en/Eton-Pharmaceuticals-Announces-FDA-Approval-of-Orphan-Drug-ALKINDI-SPRINKLE-hydrocortisone-as-Replacement-Therapy-in-Pediatric-Patients-with-Adrenocortical-Insufficiency.html
    0
    • now is going up to 12$!they have the FDA APPROVAL:)!
      1
      • Wt?? Thqts not true
        0
    • is a trap:))
      0
      • eney news about FDA approval!??
        0
        • https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process
          0
      • wow!is gonna fly up!
        1
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.